Antidepressants and Somatic Symptoms: Therapeutic Actions Are Expanding Beyond Affective Spectrum Disorders to Functional Somatic Syndromes

Stephen M. Stahl, M.D., Ph.D.

**Issue:** Having expanded their original role as primary treatment for depression to preferred treatment for anxiety disorders, antidepressants are now emerging as potential therapeutic agents for many other disorders characterized by distressing or even painful somatic symptoms.

Antidepressant Uses: The Emerging Frontier

The expanded use of antidepressants beyond the treatment of major depressive disorder (MDD) to numerous additional affective and anxiety disorders is one of the remarkable therapeutic advances in psychiatry of the past decade. Thus, numerous antidepressants now have proven efficacy in premenstrual dysphoric disorder, bulimia, panic disorder, generalized anxiety disorder, social anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder (Table 1). This expansion appears not yet to be complete, and another remarkable therapeutic advance in psychiatry may be in the offing for the coming decade.

Numerous conditions that have high comorbidity with depression but are themselves characterized by prominent somatic symptoms may also be treated effectively with antidepressants. The frontier for yet further therapeutic uses of antidepressants has thus shifted from depression and anxiety to illnesses considered either to be components of an affective spectrum disorder (Table 1) or to be members of a category known as “functional somatic syndromes” (Table 2). Prominent conditions with encouraging new findings suggesting efficacy of antidepressants include not only fibromyalgia and irritable bowel syndrome, but also a variety of chronic pain conditions.

Do Conditions That Respond to the Same Drugs Have the Same Pathophysiology?

It is plausible that conditions that respond to numerous classes of antidepressants may share a common causal factor. This does not necessarily mean that depression causes these conditions (listed in Tables 1 and 2), but it does imply that boosting serotonergic neurotransmission, noradrenergic neurotransmission, or both with an antidepressant may compensate for a common causal factor in each of these conditions. That factor might be abnormally functioning neuronal circuits that are regulated by serotonin (5-HT) and/or norepinephrine (NE). Circuits in one part of the CNS may mediate symptoms of sadness and depressed mood, and in another, anxiety and fear, and in still other areas, diffuse and often painful somatic complaints. Boosting 5-HT and/or NE neurotransmission in one circuit may reduce sadness, and in another circuit, somatic symptoms.

In MDD, some patients may experience improvement of their sadness and depressed mood, but not their somatic symptoms, while taking an antidepressant. These individuals are not in full remission. Increasing attention is being paid to recognizing and treating those with depression who experience less than full remission of symptoms, which has led recently to a much-enhanced appreciation of just how common yet frequently neglected somatic symptoms are in mood and anxiety disorders. Targeting both 5-HT and NE in neuronal circuits that mediate somatic symptoms is the therapeutic strategy most widely employed to reduce these somatic...
Table 1. Affective Spectrum Disorder

<table>
<thead>
<tr>
<th>Mood disorders</th>
<th>Anxiety disorders</th>
<th>Other disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major depress</td>
<td>Generalized anxiety disorder</td>
<td>Attention-deficit/hyperactivity disorder</td>
</tr>
<tr>
<td>Dysthymic dis</td>
<td>Panic disorder</td>
<td>Bulimia nervosa</td>
</tr>
<tr>
<td>Premenstrual dysphoric disorder</td>
<td>Obsessive-compulsive disorder</td>
<td>Cataplexy</td>
</tr>
</tbody>
</table>

Table 2. Functional Somatic Syndrome

<table>
<thead>
<tr>
<th>Conditions with prominent painful somatic symptoms</th>
<th>Conditions with distressful and often vague somatic symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibromyalgia</td>
<td>Chronic fatigue syndrome</td>
</tr>
<tr>
<td>Chronic cervical or lumbar back pain</td>
<td>Somatoform disorder</td>
</tr>
<tr>
<td>Irritable bowel syndrome</td>
<td>Multiple chemical sensitivity</td>
</tr>
<tr>
<td>Temporomandibular joint syndrome</td>
<td>Exposure syndromes (Gulf War illnesses; “sick-building syndrome”)</td>
</tr>
</tbody>
</table>

Take-Home Points

- All known antidepressants act upon monoamine neurotransmitter systems, usually by inhibiting a presynaptic transporter often called a reuptake pump. This psychopharmacologic action has resulted not only in effective antidepressants but also broadly useful anxiolytics across a spectrum of affective and anxiety disorders.
- Patients who suffer primarily from an affective or anxiety disorder commonly experience somatic symptoms that are distressing or even painful and which must be eliminated by antidepressant treatment for full remission of the affective or anxiety disorder to occur.
- A very high number of patients suffer from distressing or even painful somatic symptoms that are not recognized as part of an affective or anxiety disorder but are increasingly being shown nevertheless to respond to treatment with antidepressants. This treatment response represents a potential opportunity to expand the vistas of antidepressant therapy to a wider range of functional somatic syndromes.

REFERENCES